Business Context and Reporting Period
This Form 8-K Current Report, filed on June 26, 2026, by Innventure, Inc. (INV), discloses a significant leadership transition. The report details the retirement of the current Chief Executive Officer and the appointment of a successor, effective October 1, 2026.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and personnel changes.
Material Changes
- Departure of CEO: Gregory W. Haskell will retire as Chief Executive Officer and Class I director effective October 1, 2026. The departure is not due to any disagreement with the Company.
- Appointment of CEO: Dr. William Grieco has been appointed as the new Chief Executive Officer and Class I director, effective October 1, 2026. Dr. Grieco previously served as the Company's Chief Technology Officer (2022-2024) and is the founding CEO of Refinity, a Company subsidiary.
Guidance, Outlook, and Compensation Details
The filing outlines specific compensation arrangements for both the departing and incoming executives:
- Gregory W. Haskell (Outgoing): Will serve as an advisor under a consulting agreement until July 15, 2027. Compensation includes reimbursement for COBRA health coverage premiums (Oct 1, 2026 - April 30, 2027) and the vesting of outstanding equity awards in Innventure and Refinity through the end of the consulting term.
- Dr. William Grieco (Incoming):
- Base Salary: $550,000 annually.
- Cash Bonus: Target opportunity of 100% of base salary (prorated for 2026).
- Initial Equity Grant: Restricted stock units (RSUs) valued at $1,000,000 upon commencement, vesting one-third annually over three years.
- Future Equity: Eligible for annual equity grants starting April 2027, with an expected grant date value of $1,500,000.
A press release regarding this transition was issued on June 30, 2026.
Investor Verification Checklist
- Verify the full terms of the Consulting Agreement (Exhibit 10.1) and Employment Letter (Exhibit 10.2) for any additional clauses not summarized in the 8-K.
- Review the Company's Definitive Proxy Statement filed on April 30, 2026, for broader context on executive benefit plans.
- Monitor the press release (Exhibit 99.1) for any strategic commentary regarding the leadership change.
- Confirm the vesting schedules and conditions for the $1,000,000 RSU grant to Dr. Grieco.